What are the characteristics of VALNEVA stock?

VALNEVA is a company operating in the Vaccins et laboratoires de recherche sector. The stock is listed on Euronext Paris under ISIN FR0004056851.

What is the recent price evolution of VALNEVA stock?

Since last close: -1.91 %. Over one week: -2.39 %. Over one year: -25.84 %.

Valneva to Attend the 2026 World Vaccine Congress in Washington

Valneva has announced its participation in several events at the 26th World Vaccine Congress, which will be held from March 31 to April 2, 2026, in Washington, D.C. This involvement highlights the company's presence among key players in the vaccine sector.

Published on Mar 26, 2026 at 16:52

VALNEVA

2.82 € -1.91 %

Add us as a preferred source on Google

Valneva will participate in several events during the 26th World Vaccine Congress. This international event will take place from March 31 to April 2, 2026, at the Walter E. Washington Convention Center in Washington, D.C.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Santé

🗞️ Sanofi shares lose ground and fall back to their lowest level in a year 🗞️ Abivax stock declines but retains nearly 38% gain over one year 🗞️ Medincell stock plunges 22% in three months and breaks through its support levels 🗞️ MaaT Pharma: Negative CHMP Voting Trend on MaaT013 (Xervyteg)

Context

Period

Period: S1 2026

Key reported figures

Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros

Guidance from the release

Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026

Risks mentioned

Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya

Opportunities identified

Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations

Outlook / guidance

Expected revenue: 147,5 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Context

Also read